Relevant Articles About Bladder Cancer Research and Clinical Trials
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy
KEY TAKEAWAYS The study aimed to assess the complementary prognostic value of radiomic parameters and ctDNA status in pts wih LARC. The radiomic with post-NAT ctDNA status and rNAR score may be prognostic for survival outcomes in LARC. Magnetic resonance imaging...
KEY TAKEAWAYS The study aimed to investigate the prognostic value of SII and clinicopathological features in patients with NETs treated with 177Lu-Dotatate LU. Researchers noticed that PRRT is more effective in lower tumor burden and pancreatic NETs; further...
KEY TAKEAWAYS The study aimed to investigate the real-world efficacy and safety of the Ram plus pac combination as a 2L treatment for advanced GC/GEJC. Ram plus pac demonstrates significant survival benefits similar to RAINBOW study findings, with no new safety...
The CheckMate 274 phase 3 trial aimed to evaluate the long-term impact of adjuvant nivolumab on OS in patients with bladder cancer. The …
The phase 2 trial aimed to investigate the utility of uMRD profiling in predicting recurrence and assessing response to nadofaragene firadenovec therapy in …
The study aimed to present the updated result on efficacy of neoadjuvant N + I in cisplatin-ineligible patients with UTUC. The primary endpoint …
Introduction Immune checkpoint inhibitors (ICIs) can elicit anticancer immune responses, but predictive biomarkers are needed. We measured programmed death ligand 1 (PD-L1) expression in organs and lymph nodes using 18F-BMS-986192 positron emission tomography (PET)-imaging and looked …
Introduction Treatment with the immune checkpoint inhibitor anti-programmed cell death protein-1 (PD-1) often causes immune-related adverse events (irAEs). Since irAEs resemble autoimmune diseases, autoantibodies might play a role and could potentially be used to identify patients …
Background How distinct methods of host preconditioning impact the efficacy of adoptively transferred antitumor T helper cells is unknown. Methods CD4+ T cells with a transgenic T-cell receptor that recognize tyrosinase-related peptide (TRP)-1 melanoma antigen were polarized to …
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment for various hematological malignancies. Still, its remarkable efficacy is accompanied by unique adverse events that must be carefully managed. This comprehensive literature review …